Top Markets
Coin of the day
Hoth Therapeutics, Inc. Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc.

HOTH
Rank in Stocks #32246
Hoth Therapeutics, Inc. engages in the development of new generation therapies... Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Share Price
$0.8013
Last synced: 2026-08-05
Market Cap
$10.62M
Change (1 day)
0.97%
Change (1 year)
-37.88%
Country
US
Trade Hoth Therapeutics, Inc. (HOTH)

Category

P/S ratio for Hoth Therapeutics, Inc. (HOTH)
P/S ratio as of 2026 TTM: 0
According to Hoth Therapeutics, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Hoth Therapeutics, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
- -
KR